N@N

Berman DeValerio Announces Investigation Into MannKind Corp.

^{Published on 2010-11-05 11:26:15 - Market Wire}
 

BOSTON--([ BUSINESS WIRE ])--The law firm of Berman DeValerio is investigating possible violations of securities law and/or breaches of fiduciary duty by MannKind Corp. (Nasdaq: MNKD) ("MannKind" or the "Company") and its officers and directors.

The investigation was initiated today on news that MannKind's former senior director for regulatory affairs filed a lawsuit accusing the Company of covering up potential fraud in clinical trials for a new diabetes treatment. In his September lawsuit, the former employee, John Arditi, claims that he was fired by the Company after discovering possible fraud in studies for the drug, Afrezza. The U.S. Food and Drug Administration was set to rule on the biotech companys diabetes treatment by December 29.

If you have information regarding these allegations or are a MannKind shareholder who would like to learn about your legal options, you may contact the following attorneys at Berman DeValerio for more information.

This notice may constitute attorney advertising.